2017 Press Releases

    2017 | 2016 | 2015 | 2014 | 2013
    October 10, 2017
    Blueprint Medicines Announces Appointment of Christopher Murray, Ph.D. as Senior Vice President, Technical Operations
    September 10, 2017
    Blueprint Medicines Announces New Data from Ongoing Phase 1 Clinical Trial of BLU-554 in Patients with Advanced Hepatocellular Carcinoma
    September 06, 2017
    Blueprint Medicines to Present at Morgan Stanley 15th Annual Global Healthcare Conference
    August 21, 2017
    Blueprint Medicines to Present Updated Data from Ongoing Phase 1 Clinical Trial of BLU-554 in Patients with Advanced Hepatocellular Carcinoma at ESMO 2017 Congress and 11th ILCA Annual Conference
    August 03, 2017
    Blueprint Medicines to Present at Upcoming Investor Conferences in August
    August 02, 2017
    Blueprint Medicines Reports Second Quarter 2017 Financial Results
    July 27, 2017
    Blueprint Medicines to Evaluate Opportunities to Advance Rare Disease Discovery Program in Fibrodysplasia Ossificans Progressiva Following Discontinuation of Collaboration with Alexion
    July 26, 2017
    Blueprint Medicines to Report Second Quarter 2017 Financial Results on Wednesday, August 2, 2017
    June 05, 2017
    Blueprint Medicines Announces New Phase 1 Clinical Data for BLU-285 in Advanced Gastrointestinal Stromal Tumors and Plans to Pursue Expedited Development in Patients with a PDGFRα D842V Mutation
    June 01, 2017
    Blueprint Medicines to Present at Upcoming Investor Conferences in June
    May 17, 2017
    Blueprint Medicines to Present New Data from Ongoing Phase 1 Clinical Trial of BLU-285 in Patients with Advanced Gastrointestinal Stromal Tumors at 2017 ASCO Annual Meeting
    May 03, 2017
    Blueprint Medicines Reports First Quarter 2017 Financial Results
    April 26, 2017
    Blueprint Medicines to Report First Quarter 2017 Financial Results on Wednesday, May 3, 2017
    April 04, 2017
    Blueprint Medicines Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares of Common Stock
    March 29, 2017
    Blueprint Medicines Announces Pricing of Public Offering of Shares of Common Stock
    March 29, 2017
    Blueprint Medicines Announces Proposed Public Offering of Shares of Common Stock
    March 27, 2017
    Blueprint Medicines to Present on BLU-285 and BLU-554 at Upcoming Scientific Conferences
    March 20, 2017
    Blueprint Medicines Announces Enrollment of First Patient in Phase 1 Clinical Trial for BLU-667
    March 09, 2017
    Blueprint Medicines Reports Fourth Quarter and Full Year 2016 Financial Results
    March 02, 2017
    Blueprint Medicines to Report Fourth Quarter and Full Year 2016 Financial Results on Thursday, March 9, 2017
    February 28, 2017
    Blueprint Medicines to Present at Upcoming Investor Conferences in March
    February 15, 2017
    Blueprint Medicines to Present at 2017 RBC Capital Markets Global Healthcare Conference


    Print Page  | E-mail Page  | RSS Feeds  | E-mail Alerts  | Financial Tear Sheet